J&J DARZALEX Combos Show Positive Results for Multiple Myeloma: ASH

Updated Phase 3 ALCYONE results, featured as oral presentation at ASH 2018, showimproved progression-free survival in newly diagnosed patients
· Data from Phase 2 LYRA and GRIFFIN studies support the safety and efficacy of DARZALEX combination treatments in newly diagnosed and relapsed patients, including the feasibility of a split first dose

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term results from the Phase 3 ALCYONE study showing that the addition of DARZALEX^® (daratumumab) to bortezomib, melphalan and prednisone (VMP) continued to demonstrate significant improvement in progression-free survival (PFS) in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).¹ These data (Abstract #156), as well as updates from the Phase 2 LYRA (Abstract #152) and GRIFFIN (Abstract #151) studies in patients with multiple myeloma, were featured during an oral abstract session at the 60^th American Society of Hematology (ASH) Annual Meeting in San Diego, CA.

https://www.marketscreener.com/JOHNSON-JOHNSON-4832/news/Johnson-Johnson-DARZALEX-daratumumab-Combination-Regimens-Show-Positive-Results-for-Newly-Dia-27693119/